Education:
1988-89 : Industrial Post Doc in Quest International (Ashford, Kent, UK). Research of new synthetic routes for
organoleptic terpenes.
1987-88 : Post Doc TEXAS A&M University, Texas, USA, (Professor D.H.R. Barton). Selective
oxidation of alcanes to ketones, discovery of a new oxidation system, the Gif IV system.
1983-86 : Ph D at the Institut de Chimie des Substances Naturelles, CNRS, Gif-sur-Yvette, France, (Professor
D.H.R. Barton). Research of Radicals in O and C phenylation Reaction with Pentavalent
Bismuth compounds.
Career:
2004-2012 : Team leader in Sanofi-Aventis Pharma France, oncology group (CRVA).
2000-2004 : Lab Head in Aventis Pharma France (in charge of a medicinal chemistry lab 8-10 people).
1999-2000 : Section manager in a medicinal chemistry department. Rhône-Poulenc Rorer (RPR, Dagenham,
Essex, UK). Supervise a team of 6 to 8 people including 2 PhDs.
1998 : Senior Research Fellow (RPR). Supervise 3 to 4 synthetic chemists
1992 : Principal scientist 4 (RPR). Supervise 2 to 3 synthetic chemists
1990 : Medicinal chemist (RP), Supervise 1 synthetic chemist.
Work experience in different therapeutic areas, cardiovascular (ACAT, angiotensin II, endothelin, PDGF and C5a), Respiratory/Inflammation (RANTES antagonists, prolyl-4-hydroxylase antagonists, VLA-4, CCR2, CCR3, CCR4 antagonists, p38 inhibitors, and cathepsin S inhibitors), anti-infective (Methionine Amino Peptidase and Secretases), oncology (angiogenesis KDR, Tie2, CDKs, IGF-1R,CDKs, HSP90, PI3K, MEK) and CNS (Alzheimer diseases, PDE4, PAK3, CK1).
Track records : participation to 6 different programs leading to 7 compounds sent to preclinical development:
- 1996 endothelin ETA antagonist for the treatment of chronic obstructive pulmonary disease (COPD)
- 1999 p38 inhibitor for the treatment of rheumatoid arthritis
- 2003 CK1- inhibitor for the treatment circadian rhythm disorders
- 2004 PDE4 inhibitor for the treatment of cognitive disorders and Alzheimer disease
- 2004 Tie2/KDR inhibitor for the treatment of solid tumors
- 2006 a second Tie2/KDR inhibitor for the treatment of solid tumors
- 2010 PI3K inhibitor for the treatment of PTEN deficient solid tumors